Literature DB >> 17038474

Serious infections with antirheumatic therapy: are biologicals worse?

K L Winthrop1.   

Abstract

This paper reviews the current evidence for the role of antirheumatic therapy in the development of serious infections in patients with rheumatoid arthritis (RA). Prednisone is clearly associated with increased infectious risk, but no definitive data link methotrexate to infection. Emerging data suggest that biological agents also pose increase infectious risk, particularly when used in combination with corticosteroids or methotrexate. Further research is needed in this important aspect of RA treatment. In the meantime, the author recommends that physicians should remain vigilant for serious infections in their patients with RA and use appropriate vaccines and screening procedures to mitigate their risk.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17038474      PMCID: PMC1798385          DOI: 10.1136/ard.2006.058503

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  36 in total

1.  A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.

Authors:  J M Bathon; R W Martin; R M Fleischmann; J R Tesser; M H Schiff; E C Keystone; M C Genovese; M C Wasko; L W Moreland; A L Weaver; J Markenson; B K Finck
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

2.  Disseminated histoplasmosis presenting as pancytopenia in a methotrexate-treated patient.

Authors:  Punitha Arunkumar; Tonya Crook; James Ballard
Journal:  Am J Hematol       Date:  2004-09       Impact factor: 10.047

3.  Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.

Authors:  Lars Klareskog; Désirée van der Heijde; Julien P de Jager; Andrew Gough; Joachim Kalden; Michel Malaise; Emilio Martín Mola; Karel Pavelka; Jacques Sany; Lucas Settas; Joseph Wajdula; Ronald Pedersen; Saeed Fatenejad; Marie Sanda
Journal:  Lancet       Date:  2004-02-28       Impact factor: 79.321

4.  Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society.

Authors: 
Journal:  MMWR Recomm Rep       Date:  2000-06-09

5.  Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial.

Authors:  E William St Clair; Désirée M F M van der Heijde; Josef S Smolen; Ravinder N Maini; Joan M Bathon; Paul Emery; Edward Keystone; Michael Schiff; Joachim R Kalden; Ben Wang; Kimberly Dewoody; Roberta Weiss; Daniel Baker
Journal:  Arthritis Rheum       Date:  2004-11

Review 6.  Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management.

Authors:  Michael A Gardam; Edward C Keystone; Richard Menzies; Steven Manners; Emil Skamene; Richard Long; Donald C Vinh
Journal:  Lancet Infect Dis       Date:  2003-03       Impact factor: 25.071

7.  Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate.

Authors:  Mark C Genovese; Stanley Cohen; Larry Moreland; Deborah Lium; Sean Robbins; Richard Newmark; Pirow Bekker
Journal:  Arthritis Rheum       Date:  2004-05

8.  Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study.

Authors:  Michele F Doran; Cynthia S Crowson; Gregory R Pond; W Michael O'Fallon; Sherine E Gabriel
Journal:  Arthritis Rheum       Date:  2002-09

9.  Predictors of infection in rheumatoid arthritis.

Authors:  Michele F Doran; Cynthia S Crowson; Gregory R Pond; W Michael O'Fallon; Sherine E Gabriel
Journal:  Arthritis Rheum       Date:  2002-09

10.  Granulomatous infectious diseases associated with tumor necrosis factor antagonists.

Authors:  R S Wallis; M S Broder; J Y Wong; M E Hanson; D O Beenhouwer
Journal:  Clin Infect Dis       Date:  2004-04-15       Impact factor: 9.079

View more
  9 in total

1.  Necrotizing fasciitis and septic shock related to the uncommon gram-negative pathogen Sphingobacterium multivorum.

Authors:  D Grimaldi; A Doloy; J Fichet; E Bourgeois; B Zuber; A Wajsfisz; J P Mira; C Poyart; F Pène
Journal:  J Clin Microbiol       Date:  2011-11-09       Impact factor: 5.948

2.  Opioid Analgesics and the Risk of Serious Infections Among Patients With Rheumatoid Arthritis: A Self-Controlled Case Series Study.

Authors:  Andrew D Wiese; Marie R Griffin; C Michael Stein; Edward F Mitchel; Carlos G Grijalva
Journal:  Arthritis Rheumatol       Date:  2016-02       Impact factor: 10.995

Review 3.  Bedfellows: mycobacteria and rheumatoid arthritis in the era of biologic therapy.

Authors:  Kevin L Winthrop; Michael Iseman
Journal:  Nat Rev Rheumatol       Date:  2013-06-25       Impact factor: 20.543

4.  Rheumatoid lung disease.

Authors:  Kevin K Brown
Journal:  Proc Am Thorac Soc       Date:  2007-08-15

5.  Interferon-Beta Therapy of Multiple Sclerosis Patients Improves the Responsiveness of T Cells for Immune Suppression by Regulatory T Cells.

Authors:  Bettina Trinschek; Felix Luessi; Catharina C Gross; Heinz Wiendl; Helmut Jonuleit
Journal:  Int J Mol Sci       Date:  2015-07-17       Impact factor: 5.923

6.  The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis.

Authors:  Kevin L Winthrop; Joel Silverfield; Arthur Racewicz; Jeffrey Neal; Eun Bong Lee; Pawel Hrycaj; Juan Gomez-Reino; Koshika Soma; Charles Mebus; Bethanie Wilkinson; Jennifer Hodge; Haiyun Fan; Tao Wang; Clifton O Bingham
Journal:  Ann Rheum Dis       Date:  2015-03-20       Impact factor: 19.103

7.  Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study.

Authors:  Bella Mehta; Sofia Pedro; Gulsen Ozen; Andre Kalil; Frederick Wolfe; Ted Mikuls; Kaleb Michaud
Journal:  RMD Open       Date:  2019-06-09

8.  "Serious skin & soft tissue infections in rheumatoid arthritis patients taking anti-tumor necrosis factor alpha drugs: a nested case-control study".

Authors:  Ngoc J Wasson; Cara D Varley; Pascal Schwab; Rongwei Fu; Kevin L Winthrop
Journal:  BMC Infect Dis       Date:  2013-11-11       Impact factor: 3.090

Review 9.  The Emerging Jamboree of Transformative Therapies for Autoimmune Diseases.

Authors:  José M Carballido; Camille Regairaz; Celine Rauld; Layla Raad; Damien Picard; Michael Kammüller
Journal:  Front Immunol       Date:  2020-03-31       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.